Valmark Advisers Inc. Has $2.24 Million Holdings in Quanterix Co. (NASDAQ:QTRX)

Valmark Advisers Inc. boosted its stake in shares of Quanterix Co. (NASDAQ:QTRX) by 88.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 210,878 shares of the company’s stock after buying an additional 98,883 shares during the period. Valmark Advisers Inc. owned about 0.55% of Quanterix worth $2,242,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in Quanterix during the 3rd quarter worth about $60,000. Peapack Gladstone Financial Corp acquired a new stake in Quanterix during the 3rd quarter worth about $131,000. SG Americas Securities LLC acquired a new stake in Quanterix during the 3rd quarter worth about $139,000. Intech Investment Management LLC acquired a new stake in Quanterix during the 3rd quarter worth about $170,000. Finally, Tallon Kerry Patrick acquired a new stake in Quanterix during the 4th quarter worth about $169,000. Institutional investors and hedge funds own 86.48% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, TD Cowen lifted their target price on Quanterix from $13.50 to $16.00 and gave the company a “hold” rating in a research note on Wednesday, November 13th.

Quanterix Price Performance

NASDAQ:QTRX opened at $8.05 on Monday. Quanterix Co. has a fifty-two week low of $7.49 and a fifty-two week high of $29.70. The stock’s 50-day moving average is $9.96 and its two-hundred day moving average is $11.74. The stock has a market cap of $310.09 million, a PE ratio of -7.59 and a beta of 1.33.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings results on Monday, December 23rd. The company reported ($0.22) EPS for the quarter. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. On average, equities research analysts anticipate that Quanterix Co. will post -0.98 earnings per share for the current year.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.